Form 8-K

8-K — ABBOTT LABORATORIES

Accession: 0001628280-26-025365

Filed: 2026-04-16

Period: 2026-04-16

CIK: 0000001800

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — abt-20260416.htm (Primary)

EX-99.1 (abt-2026q1xexhibitx991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: abt-20260416.htm · Sequence: 1

abt-20260416

0000001800FALSENew York Stock ExchangeCHX00000018002026-04-162026-04-160000001800exch:XNYS2026-04-162026-04-160000001800exch:XCHI2026-04-162026-04-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

_______________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

April 16, 2026

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

_______________________________________________________

Illinois 1-2189 36-0698440

(State or other Jurisdiction

of Incorporation) (Commission File Number) (IRS Employer

Identification  No.)

_______________________________________________________

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

Trading

Symbol(s)

Name of Each Exchange

on Which Registered

Common Shares, Without Par Value ABT

New York Stock Exchange

NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Exhibit

99.1

Press Release dated April 16, 2026 (furnished pursuant to Item 2.02).

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES

Date: April 16, 2026 By: /s/ Philip P. Boudreau

Philip P. Boudreau

Executive Vice President, Finance and Chief Financial Officer

EX-99.1

Filename: abt-2026q1xexhibitx991.htm · Sequence: 2

Document

Exhibit 99.1

News Release

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

–First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent

–Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market

–Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1

–Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences

ABBOTT PARK, Ill., April 16, 2026 — Abbott today announced financial results for the first quarter ended March 31, 2026.

•First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.

•First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.

•On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio.

•Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.

•Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

•In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.

•In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).

•In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre® achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.

"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."

Page 1 of 15

FIRST-QUARTER BUSINESS OVERVIEW

Comparable sales growth:

Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices

U.S. 4,274 844 905 — 2,523

International 6,890 1,173 1,275 1,426 3,016

Total reported 11,164 2,017 2,180 1,426 5,539

% Change vs. 1Q25

U.S. 2.5 (11.6) 3.8 n/a 7.9

International 11.3 (1.5) 7.8 13.2 18.0

Total reported 7.8 (6.0) 6.1 13.2 13.2

Total reported excl. foreign exchange impact 3.8 (7.7) 2.5 9.0 8.1

Comparable sales growth 3.7 (7.7) 1.8 9.0 8.5

U.S. 2.5 (11.6) 2.0 n/a 8.7

International 4.6 (4.7) 1.6 9.0 8.3

Refer to page 13 for a reconciliation of comparable sales growth.

Page 2 of 15

Nutrition

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Pediatric Adult

U.S. 844 511 333

International 1,173 442 731

Total reported 2,017 953 1,064

% Change vs. 1Q25

U.S. (11.6) (13.0) (9.2)

International (1.5) (2.6) (0.9)

Total reported (6.0) (8.5) (3.6)

Total reported excl. foreign exchange impact (7.7) (9.7) (5.9)

Comparable sales growth (7.7) (9.7) (5.9)

U.S. (11.6) (13.0) (9.2)

International (4.7) (5.3) (4.3)

Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of several new products, are expected to contribute to improved volume growth over the course of the year.

Page 3 of 15

Diagnostics*

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics

U.S. 905 347 93 465

International 1,275 925 3 347

Total reported 2,180 1,272 96 812

% Change vs. 1Q25

U.S. 3.8 4.5 n/a (13.8)

International 7.8 9.5 n/a 2.8

Total reported 6.1 8.1 n/a (7.4)

Total reported excl. foreign exchange impact 2.5 3.3 n/a (9.6)

Comparable sales growth 1.8 3.3 13.4 (9.6)

U.S. 2.0 4.5 13.2 (13.8)

International 1.6 2.8 19.2 (2.7)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to page 13 for a reconciliation of comparable sales growth.

Worldwide Diagnostics sales increased 6.1 percent on a reported basis and increased 1.8 percent on a comparable basis.

Worldwide Core Laboratory Diagnostics results were driven by growth in the U.S., Europe and Latin America. Sales of Core Laboratory diagnostic tests increased on both a year-over-year and sequential basis.

Rapid and Molecular Diagnostics results reflect lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.

Results in Cancer Diagnostics reflect Abbott's acquisition of Exact Sciences, which closed on March 23, 2026. Growth in Cancer Diagnostics was driven by double-digit growth of Cologuard® and sales of Cancerguard®, a multi-cancer screening test that launched last year.

Page 4 of 15

Established Pharmaceuticals

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Key Emerging Markets Other

U.S. — — —

International 1,426 1,089 337

Total reported 1,426 1,089 337

% Change vs. 1Q25

U.S. n/a n/a n/a

International 13.2 12.9 14.1

Total reported 13.2 12.9 14.1

Total reported excl. foreign exchange impact 9.0 9.4 7.9

Comparable sales growth 9.0 9.4 7.9

U.S. n/a n/a n/a

International 9.0 9.4 7.9

Established Pharmaceuticals sales increased 13.2 percent on a reported basis and 9.0 percent on a comparable basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 12.9 percent on a reported basis and 9.4 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.

Page 5 of 15

Medical Devices

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Rhythm Management Electro-

physiology* Heart Failure Vascular Structural Heart* Neuromodulation Diabetes Care

U.S. 2,523 339 378 292 291 224 177 822

International 3,016 345 410 97 486 354 66 1,258

Total reported 5,539 684 788 389 777 578 243 2,080

% Change vs. 1Q25

U.S. 7.9 11.5 13.7 11.4 8.6 (9.5) 0.7 9.8

International 18.0 22.9 19.6 25.2 10.0 25.2 27.2 16.6

Total reported 13.2 17.0 16.7 14.6 9.5 9.0 6.8 13.8

Total reported excl. foreign exchange impact 8.1 12.5 12.5 12.2 4.9 3.6 4.1 7.4

Comparable sales growth 8.5 12.5 12.5 12.2 4.9 6.8 4.1 7.4

U.S. 8.7 11.5 13.7 11.4 8.6 (3.6) 0.7 9.8

International 8.3 13.5 11.2 14.9 2.7 15.0 15.5 5.7

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

Refer to page 13 for a reconciliation of comparable sales growth.

Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 14.2 percent on a reported basis and 7.6 percent on a comparable basis.

Page 6 of 15

Abbott's Financial Guidance

Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 409th Consecutive Quarterly Dividend

On Feb. 20, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

Page 7 of 15

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Financial:

Michael Comilla, 224-668-1872

Tamika McLoughlin, 224-399-5082

Randy Blakley, 224-668-0036

Abbott Media:

Karen Twigg May, 224-668-2681

Kate Dyer, 224-668-9965

1.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.

Page 8 of 15

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Quarter Ended March 31, 2026 and 2025

(in millions, except per share data)

(unaudited)

1Q26 1Q25 % Change

Net Sales $11,164 $10,358 7.8

Cost of products sold, excluding amortization expense 4,890 4,468 9.5

Amortization of intangible assets 422 420 0.3

Research and development 767 716 7.2

Selling, general, and administrative 3,740 3,061 22.2

Total Operating Cost and Expenses 9,819 8,665 13.3

Operating Earnings 1,345 1,693 (20.6)

Interest expense, net 68 49 37.4

Net foreign exchange (gain) loss (13) (7) n/m

Other (income) expense, net (159) (127) 24.8

Earnings before taxes 1,449 1,778 (18.5)

Taxes on Earnings 372 453 (18.0) 1)

Net Earnings $1,077 $1,325 (18.7)

Net Earnings excluding Specified Items, as described below $2,022 $1,919 5.4 2)

Diluted Earnings per Common Share $0.61 $0.76 n/m

Diluted Earnings per Common Share, excluding Specified Items, as described below $1.15 $1.09 5.5 2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,747 1,747

NOTES:

See tables on page 11 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

Page 9 of 15

1)2026 Taxes on Earnings includes the recognition of approximately $50 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $945 million, or $0.54 per share, for intangible amortization, charges related to restructuring, acquisitions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of $594 million, or $0.33 per share, for intangible amortization, charges related to investment impairments, restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Page 10 of 15

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

First Quarter Ended March 31, 2026 and 2025

(in millions, except per share data)

(unaudited)

1Q26

As Reported (GAAP) Specified Items As Adjusted

Intangible Amortization

$ 422 $ (422) $ —

Gross Margin

5,852 432 6,284

R&D

767 (24) 743

SG&A

3,740 (473) 3,267

Other (income) expense, net

(159) (7) (166)

Earnings before taxes

1,449 936 2,385

Taxes on Earnings

372 (9) 363

Net Earnings

1,077 945 2,022

Diluted Earnings per Share

$ 0.61 $ 0.54 $ 1.15

Specified items reflect intangible amortization expense of $422 million and other net expenses of $514 million associated with restructuring actions, acquisitions, and other net expenses. See page 14 for additional details regarding specified items.

1Q25

As Reported (GAAP) Specified Items As Adjusted

Intangible Amortization

$ 420 $ (420) $ —

Gross Margin

5,470 448 5,918

R&D

716 (27) 689

SG&A

3,061 (10) 3,051

Other (income) expense, net

(127) (35) (162)

Earnings before taxes

1,778 520 2,298

Taxes on Earnings

453 (74) 379

Net Earnings

1,325 594 1,919

Diluted Earnings per Share

$ 0.76 $ 0.33 $ 1.09

Specified items reflect intangible amortization expense of $420 million and other net expenses of $100 million associated with restructuring actions, acquisitions, investment impairments and other net expenses. See page 15 for additional details regarding specified items.

Page 11 of 15

A reconciliation of the first-quarter tax rates for 2026 and 2025 is shown below:

1Q26

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 1,449 $ 372 25.6 % 1)

Specified items 936 (9)

Excluding specified items $ 2,385 $ 363 15.2 %

1Q25

($ in millions) Pre-Tax

Income Taxes on

Earnings Tax

Rate

As reported (GAAP) $ 1,778 $ 453 25.5 % 2)

Specified items 520 (74)

Excluding specified items $ 2,298 $ 379 16.5 %

2)2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 12 of 15

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

First Quarter Ended March 31, 2026 and 2025

($ in millions)

(unaudited)

1Q26 1Q25 % Change vs. 1Q25

Non-GAAP

Abbott Reported Impact of acquisition (a) Impact

of multi-year agreement (b) Foreign exchange Comparable Revenue Abbott Reported Impact of acquisition (a) Impact

of multi-year agreement (b) Comparable Revenue Reported Comparable

Total Company 11,164 706 (8) (414) 11,448 10,358 707 (24) 11,041 7.8 3.7

U.S. 4,274 681 (8) — 4,947 4,168 684 (24) 4,828 2.5 2.5

Intl 6,890 25 — (414) 6,501 6,190 23 — 6,213 11.3 4.6

Total Diagnostics 2,180 706 — (76) 2,810 2,054 707 — 2,761 6.1 1.8

U.S. 905 681 — — 1,586 871 684 — 1,555 3.8 2.0

Intl 1,275 25 — (76) 1,224 1,183 23 — 1,206 7.8 1.6

Total Cancer Diagnostics 96 706 — (1) 801 — 707 — 707 n/a 13.4

U.S. 93 681 — — 774 — 684 — 684 n/a 13.2

Intl 3 25 — (1) 27 — 23 — 23 n/a 19.2

Total Medical Devices 5,539 — (8) (249) 5,282 4,895 — (24) 4,871 13.2 8.5

U.S. 2,523 — (8) — 2,515 2,339 — (24) 2,315 7.9 8.7

Intl 3,016 — — (249) 2,767 2,556 — — 2,556 18.0 8.3

Total Structural Heart* 578 — (8) (29) 541 — 531 — (24) 507 9.0 6.8

U.S. 224 — (8) — 216 — 248 — (24) 224 (9.5) (3.6)

Intl 354 — — (29) 325 — 283 — — 283 25.2 15.0

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

(a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

(b) Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Page 13 of 15

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2026 and 2025

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ 2 $ 7 $ 422 $ 1 $ 432

R&D (1) (10) — (13) (24)

SG&A (444) (33) — 4 (473)

Other (income) expense, net (2) (2) — (3) (7)

Earnings before taxes $ 449 $ 52 $ 422 $ 13 936

Taxes on Earnings (d) (9)

Net Earnings $ 945

Diluted Earnings per Share $ 0.54

The table above provides additional details regarding the specified items described on page 11.

a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 14 of 15

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Quarter Ended March 31, 2025

(in millions, except per share data)

(unaudited)

Acquisition or Divestiture- related (a) Restructuring and Cost Reduction Initiatives (b) Intangible Amortization Other (c) Total Specifieds

Gross Margin $ — $ 26 $ 420 $ 2 $ 448

R&D (1) (16) — (10) (27)

SG&A (3) (7) — — (10)

Other (income) expense, net (24) — — (11) (35)

Earnings before taxes $ 28 $ 49 $ 420 $ 23 520

Taxes on Earnings (d) (74)

Net Earnings $ 594

Diluted Earnings per Share $ 0.33

The table above provides additional details regarding the specified items described on page 11.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses as well as a fair value adjustment to contingent consideration related to a business acquisition.

b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

d)Reflects the net tax benefit associated with the specified items. 2025 Taxes on Earnings includes approximately $200 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 15 of 15

GRAPHIC

Filename: image.jpg · Sequence: 7

Binary file (43759 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Apr. 16, 2026

Document Information [Line Items]

Document Type

8-K

Document Period End Date

Apr. 16, 2026

Entity Registrant Name

ABBOTT LABORATORIES

Entity Incorporation, State or Country Code

Entity File Number

1-2189

Entity Tax Identification Number

36-0698440

Entity Address, Address Line One

100 Abbott Park Road

Entity Address, City or Town

Abbott Park

Entity Address, State or Province

Entity Address, Postal Zip Code

60064-6400

City Area Code

224

Local Phone Number

667-6100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0000001800

Amendment Flag

false

NYSE CHICAGO, INC.

Document Information [Line Items]

Title of 12(b) Security

Common Shares, Without Par Value

Trading Symbol

ABT

Security Exchange Name

CHX

NEW YORK STOCK EXCHANGE, INC.

Document Information [Line Items]

Title of 12(b) Security

Common Shares, Without Par Value

Trading Symbol

ABT

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XCHI

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type:

Balance Type:

Period Type: